Close Menu

muscular dystrophy

NEW YORK (GenomeWeb News) – Drug firm Summit and the Children's National Medical Center in Washington today announced a collaboration for the development of a proteomic assay to measure biomarkers in support of Summit's candidate drug for Duchenne Muscular Dystrophy (DMD).

A team led by clinical researchers from the Emory University School of Medicine has published a paper validating the use of RainDance Technologies' multiplexed PCR-based target enrichment technology upstream of a next-generation sequencing panel for comprehensive mutational analy

Benitec Biopharma this week announced that it has obtained positive in vitro data from its early-stage program in oculopharyngeal muscular dystrophy.

By Doug Macron
Benitec Biopharma last week broke out new details about its in-house pipeline, stating that it aims to have three drugs in clinical studies next year and possibly a fourth by 2014.

By Bernadette Toner
GenomeQuest this week said that the Emory Genetics Laboratory is using its GQ-Dx software to support a suite of sequencing-based diagnostic tests it offers through its CLIA-certified facility.

Quest will have the rights to develop and offer tests based on the technology in the US, India, and Mexico.

The sequencing will be done on ABI's SOLiD, and over the next three months Emory plans to add sequencing-based testing for mitochondrial diseases, prostate cancer, hearing loss, cardiomyopathy, and various types of mental retardation.

Pages

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.